{"name":"Glenmark Pharmaceuticals Europe Ltd. (R&D)","slug":"glenmark-pharmaceuticals-europe-ltd-r-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"GRC 8200","genericName":"GRC 8200","slug":"grc-8200","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"pipeline","source":"CNBC TV18","summary":"Glenmark Pharma guides for 23% core margins in FY27 - CNBC TV18","headline":"Glenmark Pharma guides for 23% core margins in FY27 - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOcU40eU9PMVo5TGRrN2lZOWtiWjNuRXBNbjU0Z0hFUDJMUjBFWDUxOThUZmhfVzJhRVVyN1VrRy10QkVFbWZ0ZmxJbnZIMjBTVWhCcldTRGp3d3FUbFlmVXlxeXBYaEp0QnBZdC1RcVlaVmpqbGF1NkREWkN4d015dXNyaElrdm9EM3U0bU4xdl9IUEdRMVhTN1dNMjVuanBLdVQ0SkFqRzZEblpqY0o5T1p6SmpOMDlQdjVNNW9zMDA1Z3lUX05vOUpCRnQ0c2tIM0VqYW9nM210QkhiUUQ0WVQ4MVM4eTNTLUtmLWdVcFF2b2s?oc=5","date":"2026-01-30","type":"earnings","source":"Whalesbook","summary":"Glenmark Pharma Q3: Revenue Soars 15%, Pipeline Gains Fuel Global Optimism - Whalesbook","headline":"Glenmark Pharma Q3: Revenue Soars 15%, Pipeline Gains Fuel Global Optimism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQUkVYVkFZYjBuSXNxNHRVbFBETnpORWVuQnZYQ3BVV2ZYSWxEWU1zOUxaVkQxZXFvTjV6NjdrZWE2QjBnblZTdmh5RlZlVHlxeW5uZGdCWHlBcEJ2Z0VWeVF4SlZ0V0RTQVJKdnVnMzFaeFZ2TktRRl9xSmJ4RDk0bUhjU09odnBaTVlzR3RySjRCQ0hvLXltM0Q0QWthVldQLUw3RVlNVU9nZHpLdXM0bDFzSnRXNXItcVZfVXJTbkh5dUNtS3hPbGpFbw?oc=5","date":"2025-10-07","type":"pipeline","source":"LinkedIn","summary":"Global pharmaceutical giant Eli Lilly and Company has announced a ₹9,000 crore investment to establish a large-scale manufacturing and quality hub in Hyderabad. The decision follows a meeting between ","headline":"Global pharmaceutical giant Eli Lilly and Company has announced a ₹9,000 crore investment to establish a large-scale man","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwJBVV95cUxPOTc5MFJSTEVKUmlSa0lQenNtMGszRUlaamFrYk45U2h6eFRSeFFPSkJ2STJiOWF0YkNpbVZXZ3J0V0gyRFQ1ODB3dmVMWGtPeGZnMlBoRWg1M253cFVfNTVIMm5VM1EwNVhZdmVRWmYwOVA4bWdFTmlQektSWmtXVmdvU0w5VUxGLTNSVzlVd0xTZlBMQWx0VnFBczduZ2tsTVlYbmJUdEhkYVZiekUyWk5nM3pVN3VKaXA1MlRKbl9VMkJucnREcEtKeXY3XzRLa29KNGVaOVJXeTRrSmxRbElpNXlDWG04dzZ1UXdTbTlZc1ZmRk1KT0tFUTRFYlhoWWVHal9xQnJuTGpac2JnVW1mbk9lb1FhMVpodk9EN2lGUDdSQlBMZ3Foa3k5WG8yLXd2MnNBQ3dFbTBueDVmaXpMNA?oc=5","date":"2025-09-24","type":"pipeline","source":"Business Wire","summary":"South Africa Pharmaceutical Industry Report 2025 | Market Concentration and Price Regulations Pose Challenges for South Africa's Pharma Sector - ResearchAndMarkets.com - Business Wire","headline":"South Africa Pharmaceutical Industry Report 2025 | Market Concentration and Price Regulations Pose Challenges for South ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBNUlhLRG5EMko5U1NCTTZ4dnhja0xMekw3V2VHU2ZGX0UzRklWRkdlS2FVZ3NSSlBkWjI3bkZMVlBOTmllY21pQUZkMTI1eHlFRlBmcXMtTlRrZXpQMGl6NEZMU1h0UQ?oc=5","date":"2025-07-30","type":"pipeline","source":"HDFC Sky","summary":"Glenmark Pharma Share Price - HDFC Sky","headline":"Glenmark Pharma Share Price","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-11","type":"deal","source":"outlookbusiness.com","summary":"How Glenmark’s AbbVie Deal is a Masterclass in Indian Pharma's R&D Ambitions - outlookbusiness.com","headline":"How Glenmark’s AbbVie Deal is a Masterclass in Indian Pharma's R&D Ambitions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPVGgzRE1nM2VWaTdWZWdYaGwtVl9qcnUxTVN1eHdSLVNfM0h4c0J2QkwwRDNrRlQxQUZJS0c0b2VhX3RfSE5fSGlyNDRKb1MzejV0QU5CRlZ4VDU3Z1N0RzYtR2duM0dqYnpxWEpoSjdJVDhleXZwZGo3bjhpN2JuTHg1T0ViZlBPeXFQVlZjYUxZZmZKbWp0SDdyaHFISkN4UW43UG9tX0U0bTRqT29rekp2aFlJS1oyQWNvU1R3akZXWV9JNUs1UlFGalpLZ1dpYV9FSEIyaDdvUkV0dXZrRFY1My14LWl1dXFqUdIB8gFBVV95cUxOUEZrOXZHVGg4VHJlQm1ZckdfdkVwcWs2eFNGZWsyVE9IUzVVR0RWOXpjV2c3WU15YldyM2hLeHk3TEtteVZxdlRpOEhXdHVxOFFCTGhaUGlKbVRET2lhLVVZZmlOTWJXZ1dUenNnOU5rRV8zMHVmUVFBbDRsMTB0YUJIOGlhdHlZN3NhWEY3dGtEV245QkNQSW9wQWdLWEJ1RmpNWFhISUdTV1VJZ1c1WkJmcnNXZXpVWXAweU1xUzFVZzFZZzk1eDlsTmVYQ05FZHRMVzhwQWMxbXBzYS1fUXJkYnlYQmcxVVBNazdpTFVEdw?oc=5","date":"2025-07-11","type":"deal","source":"Moneycontrol.com","summary":"Glenmark’s R&D bet pays off handsomely with AbbVie deal, vindicating backer-in-chief Saldanha - Moneycontrol.com","headline":"Glenmark’s R&D bet pays off handsomely with AbbVie deal, vindicating backer-in-chief Saldanha","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-16","type":"pipeline","source":"medicaldialogues.in","summary":"Ipca Labs appoints Dr Nagaji Ambabhai Vekariya as President - CRD - medicaldialogues.in","headline":"Ipca Labs appoints Dr Nagaji Ambabhai Vekariya as President - CRD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPUHlOcWE1TE1obXdQOHNGbVpzZFBXelFkam10Q1RzcFNUeHdjNVRVc2ZtVHVQbFlYR1BIYUZLLWR5VktCU2xqdFFJeTdiVWNkY2lFUExEMkZJWDR4RS1xX0dTSi1ONGVidHVHTUxQVE5nZzhSYjQxUU9ZUzZmd1RET2VPeHJGV2NyRV9Kbk4yV1RubkM1ZGtmM21HdEhlMUhKeHdxUE9fUHpJMXo0SWwzRXZvcWJfOUdlZlN5Q2ZB?oc=5","date":"2024-08-19","type":"pipeline","source":"BioSpace","summary":"Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC) - BioSpace","headline":"Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQeEUzNDJzTjNIaFFsS1pUczVEUWpQeHNJdURaYXRkMURQbTN6ZEdSV3hZQzlCSHRmS3BzQk56RTlrSkY1ZVo3VmpLeUdlT0cyS20zRnAzS2dvWDBYM1dqQzdXcmZxRkVLUmRSSXRMMC1OdmdQOGhKTG9zRlFYMF9OMkc0SW5PRnBHR2xlWUJyVWZEcDBBWjlMc0NTQkZCd1J2TDJxcGJHd0R0SUNpTGh5cWpsQXJ2eFdydTdmNzVTNXFCTTg0U1FQXzY5Vm9ocmpwWGxxeC1IZ09PLXlNdlVWOXczU0pfQQ?oc=5","date":"2024-02-14","type":"earnings","source":"PR Newswire","summary":"Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24 - PR Newswire","headline":"Glenmark Pharmaceuticals Ltd. reports Consolidated Revenue of Rs. 29,096 Mn for Q3 FY 2023-24","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQaU9SdGY2LW9yTk9mZWFUYjA4dC1ueHprTHpjemlkYmpkbkRYX296LVJFOVFzX2Nub0ZzVk1NZzAxY00tbmZ0N1U1QXBhX2FMZGp3OXA0c3piLW1XVkhISUNzTHJzU3pBT2xlMWZDWUxWTTVId3BIbmJFQXVGQjZfUFZlZ3B6Nk9oTWdlQUFTVm9rREpkUFFYVXlwYWxyWWxuTEhZZ0RUTFJITGFTRVpSNUpOVnZLQ3FjUXk5V2ZoRWo3cld5cVFKOU1FcFU1ZVRvempETVFjTVpBc0xOdDBMbFV1X21PTTNDS0NkNDFNRnlCdnVFbTlyVmxEQVFUTGxZRzh4dw?oc=5","date":"2023-11-10","type":"earnings","source":"PR Newswire","summary":"Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24 - PR Newswire","headline":"Glenmark Pharma reports consolidated revenue growth of 6.3% and adjusted EBITDA growth of 8.3% YoY for Q2 FY 2023-24","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQeFBNd2RwNmlOUWFQSzMxRjBhWEJLVlV4bFYyck5ZUzl2b1hoRjhIY1NGQmxYVFoxQXVTZV85UEtiYVp0T1A2aHMzbjI4YzY4Q2V6YUFnWDUwSkhOS2dBWFZGVlQ5R0JQOWdrS3Izdmd6UXBoZDBIZlRqSEFpMmhNR1I0d2RNSXAwR014UEJWREZOb3RrQWpGbzNkYUdvX3dBUW9nNEtaYllXRmd4T25STmJB?oc=5","date":"2023-09-22","type":"pipeline","source":"Fierce Pharma","summary":"Glenmark solves its 'decade-long' debt problem with $681M sale of API unit to Nirma - Fierce Pharma","headline":"Glenmark solves its 'decade-long' debt problem with $681M sale of API unit to Nirma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}